FDA unauthorizes use of Regeneron, Eli Lilly antibody treatments; new version of omicron reported: Live COVID-19 updates
Published
The FDA said the two treatments are unlikely to work against the omicron variant, which makes up 99% of U.S. cases. Latest COVID-19 news.